Your browser doesn't support javascript.
loading
[Distribution and influencing factors of lipoprotein (a) levels in non-arteriosclerotic cardiovascular disease population in China].
Ke, Y L; Pan, L; Lyu, J; Sun, D J Y; Pei, P; Chen, Y P; Yang, L; Du, H D; Clarke, Robert; Chen, J S; Chen, Z M; Zhang, X; Chen, T; Li, R Q; Qi, L T; Li, L M; Yu, C Q.
Afiliação
  • Ke YL; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China.
  • Pan L; Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing 100191, China.
  • Lyu J; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing 100191, China Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of
  • Sun DJY; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing 100191, China Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of
  • Pei P; Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing 100191, China.
  • Chen YP; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, United Kingdom.
  • Yang L; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, United Kingdom.
  • Du HD; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, United Kingdom.
  • Clarke R; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, United Kingdom.
  • Chen JS; China National Center for Food Safety Risk Assessment, Beijing 100022, China.
  • Chen ZM; Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, United Kingdom.
  • Zhang X; Beijing Novartis Pharma Company Limited, Beijing 102200, China.
  • Chen T; Beijing Novartis Pharma Company Limited, Beijing 102200, China.
  • Li RQ; Beijing Novartis Pharma Company Limited, Beijing 102200, China.
  • Qi LT; Department of Cardiovascular Diseases, Peking University First Hospital, Beijing 100034, China.
  • Li LM; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing 100191, China Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of
  • Yu CQ; Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China Peking University Center for Public Health and Epidemic Preparedness & Response, Beijing 100191, China Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of
Zhonghua Liu Xing Bing Xue Za Zhi ; 45(6): 779-786, 2024 Jun 10.
Article em Zh | MEDLINE | ID: mdl-38889976
ABSTRACT

Objective:

To describe the distribution of lipoprotein (a) [Lp(a)] levels in non-arteriosclerotic cardiovascular disease (ASCVD) population in China and explore its influencing factors.

Methods:

This study was based on a nested case-control study in the CKB study measured plasma biomarkers. Lp(a) levels was measured using a polyclonal antibody-based turbidimetric assay certified by the reference laboratory and ≥75.0 nmol/L defined as high Lp(a). Multiple logistic regression model was used to examine the factors related to Lp(a) levels.

Results:

Among the 5 870 non-ASCVD population included in the analysis, Lp(a) levels showed a right-skewed distribution, with a M (Q1, Q3) of 17.5 (8.8, 43.5) nmol/L. The multiple logistic regression analysis found that female was associated with high Lp(a) (OR=1.23, 95%CI 1.05-1.43). The risk of increased Lp(a) levels in subjects with abdominal obesity was significantly reduced (OR=0.68, 95%CI 0.52-0.89). As TC, LDL-C, apolipoprotein A1(Apo A1), and apolipoprotein B(Apo B) levels increased, the risk of high Lp(a) increased, with OR (95%CI) for each elevated group was 2.40 (1.76-3.24), 2.68 (1.36-4.93), 1.29 (1.03-1.61), and 1.65 (1.27-2.13), respectively. The risk of high Lp(a) was reduced in the HDL-C lowering group with an OR (95%CI) of 0.76 (0.61-0.94). In contrast, an increase in TG levels and the ratio of Apo A1/Apo B(Apo A1/B) was negatively correlated with the risk of high Lp(a), with OR (95%CI) of 0.73 (0.60-0.89) for elevated triglyceride group, and OR (95%CI) of 0.60 (0.50-0.72) for the Apo A1/B ratio increase group (linear trend test P≤0.001 except for Apo A1). However, no correlation was found between Lp(a) levels and lifestyle factors such as diet, smoking, and physical activity.

Conclusions:

Lp(a) levels were associated with sex and abdominal obesity, but less with lifestyle behaviors.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Lipoproteína(a) Limite: Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: Zh Revista: Zhonghua Liu Xing Bing Xue Za Zhi Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Lipoproteína(a) Limite: Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: Zh Revista: Zhonghua Liu Xing Bing Xue Za Zhi Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: China